Dr. Jonathan Fletcher is a lab-based medical and pediatric oncologist at Harvard Medical School, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute.. His lab focus is on translational GIST and sarcoma research, where the main priority is to identify and validate novel therapeutic strategies. His research program has characterized oncogenic mechanisms in GIST and many sarcoma subtypes. They have advanced new models and biologic insights for GIST, leiomyosarcoma, MPNST, liposarcoma and endometrial stromal sarcoma, among others. His group performed preclinical validations and correlative science supporting the three FDA-approved drug applications (imatinib, sunitinib, and regorafenib) for GIST, and he coordinates international research consortia devoted to maximizing therapeutic response in GIST and leiomyosarcoma. Dr. Fletcher’s clinical activities are in cancer diagnostics, with a focus on molecular diagnostics and cytogenetics. In addition to high-throughput genomic and molecular cytogenetic studies, his group has developed methods for profiling oncogenic tyrosine kinase activation in frozen tumor specimens, and in one application identified the first PDGFRA oncoproteins. Dr. Fletcher joined the SARC Board of Directors February, 2018.